A family trust proposes selling 30,000 BridgeBio Pharma (BBIO) shares around Nov. 19, 2026.
The Kumar Haldea Family Irrevocable Trust proposes to sell 30,000 common shares of BridgeBio Pharma (BBIO), with an aggregate market value of $2,340,300, on or around November 19, 2026. This proposed sale is detailed in a Form 144 SEC filing and is being conducted under a Rule 10b5-1 plan adopted on May 13, 2026. Neil Kumar, identified as a director and officer, is associated with the trust.
Form 4 BridgeBio Pharma Inc: Thomas Trimarchi (President and CFO) For: 16 November By Investing.com
This article reports on a Form 4 filing for BridgeBio Pharma Inc., specifically detailing a transaction by Thomas Trimarchi, the company's President and CFO, on November 16. The brief announcement provides the company name, the executive's role, and the date of the reported activity.
BBIO: Director Neil Kumar proposes sale of 34,980 BridgeBio shares
BridgeBio Pharma Inc. Director Neil Kumar has filed a Form 144 to sell 34,980 shares of BBIO, valued at approximately $2.7 million. This sale, set for around November 18, 2026, is part of a pre-arranged 10b5-1 trading plan adopted on May 13, 2026. While the pre-arranged plan can be seen as positive for shareholders, the insider selling shares could also be interpreted as a negative signal by some.
Form 4 BridgeBio Pharma Inc: Thomas Trimarchi (President and CFO) For: 16 November
This article reports on a Form 4 filing for BridgeBio Pharma Inc, detailing an insider transaction by Thomas Trimarchi, who serves as President and CFO. The filing pertains to activity on November 16. The news was published on November 18, 2026, at 08:16 p.m.
Form 4 BridgeBio Pharma Inc: Maricel Apuli (Chief Accounting Officer) For: 16 November
This article reports on a Form 4 filing for BridgeBio Pharma Inc., specifically detailing a transaction related to Maricel Apuli, the Chief Accounting Officer, on November 16. Form 4 filings are required by the SEC to disclose changes in ownership of company stock by insiders. The article indicates BridgeBio Pharma's stock symbol is BBIO.
Form 4 BridgeBio Pharma Inc: Neil Kumar (Director, CEO) For: 16 November
This article reports a Form 4 filing for BridgeBio Pharma Inc, indicating that Neil Kumar, who serves as both a Director and CEO, had a transaction on November 16. The specific details of the transaction are not provided in the snippet, but it highlights insider activity for the company. The article was published on November 19, 2026, at 01:06 UTC.
A stock grant vested for BridgeBio Pharma (BBIO) CFO Thomas Trimarchi, with 22,781 shares withheld for taxes.
BridgeBio Pharma's President and CFO, Thomas Trimarchi, had 22,781 common shares withheld on November 16, 2026, to cover tax obligations related to the vesting of 41,193 restricted stock units. The reported price per share for the withholding was $77.36, and after this transaction, Trimarchi directly held 313,748 shares. This information was disclosed in a Form 4 SEC filing, indicating an insider trading activity.
BridgeBio Pharma (BBIO) chief accounting officer had 4,714 shares withheld for taxes as a stock award vested.
BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, had 4,714 shares withheld for taxes on November 16, 2026, in connection with the vesting of 9,261 restricted stock units (RSUs). The reported price per share for the withholding was $77.36. Following this transaction, Ms. Apuli directly held 115,973 shares of the company's common stock.
BBIO: Director Neil Kumar proposes sale of 34,980 BridgeBio shares
BridgeBio Pharma Inc. (BBIO) Director and Officer Neil Kumar has filed a Form 144 to sell 34,980 shares of the company, valued at approximately $2.7 million. This sale, proposed for November 18, 2026, is being conducted under a pre-arranged Rule 10b5-1 trading plan adopted in May 2026. While the pre-arranged plan can be seen as a positive for shareholders, the insider selling may be interpreted as a negative signal by some investors.
Form 4 BridgeBio Pharma Inc: Neil Kumar (Director, CEO) For: 16 November
This article reports on a Form 4 filing for BridgeBio Pharma Inc. involving Neil Kumar, who serves as a Director and CEO. The filing pertains to activities that occurred on November 16. The content provides basic information about the filing without further details.
BridgeBio Reports New AHA and ISA 2026 Data Show Early and Broad Clinical Benefit of Acoramidis in ATTR-CM
BridgeBio Pharma announced new analyses from the Phase 3 ATTRibute-CM study and real-world evidence confirming the early and broad clinical benefits of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). Findings presented at the American Heart Association and International Symposium on Amyloidosis demonstrated that acoramidis significantly reduces heart failure events by 45% versus placebo, with benefits appearing within the first month. Real-world data also showed a 23% lower risk of worsening heart failure when acoramidis was used instead of tafamidis, reinforcing its potential as a first-line treatment option.
BridgeBio at jefferies global healthcare conference: launch window ahead By Investing.com
BridgeBio Pharmaceuticals (BBIO) presented at the Jefferies Global Healthcare Conference, emphasizing an upcoming period with three product launches expected within the next seven months. The company highlighted the strong performance of its ATTRUBY product, which is already generating over $1 billion in annualized growth, and discussed its pipeline, including therapies for LGMD2I, achondroplasia, and ADH1, while addressing investor concerns about commercial outlook and label expansion.
Morgan Stanley maintains BridgeBio Pharma at Overweight, raises price target to $91 from $88
Morgan Stanley has reiterated its "Overweight" rating for BridgeBio Pharma (BBIO) and increased its price target to $91 from $88, representing a 3.4% rise. This new target suggests a 16.4% upside from the stock's closing price of $78.17 on November 12. Other analysts have recently issued price targets for BridgeBio Pharma ranging from $88 to $120.
A 14.2 million-share passive stake links Farallon to BridgeBio Pharma (BBIO).
Farallon Capital Management, L.L.C. has reported a 7.3% passive stake in BridgeBio Pharma, Inc. (BBIO), amounting to 14,247,000 shares. This ownership is held directly by various Farallon investment funds, with the investment manager and several managing members exercising shared voting and dispositive power over these shares. The SEC filing, a SCHEDULE 13G/A, indicates an event date of September 30, 2026, and was accepted by the SEC on November 12, 2026.
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
BridgeBio Pharma will present 28 abstracts, including 12 new posters, on its drug acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at the International Symposium on Amyloidosis 2026. The data aims to strengthen acoramidis's clinical profile as a first-line treatment, covering kidney function, real-world outcomes, and treatment patterns. Bayer, BridgeBio's European partner, will also share new real-world data comparing acoramidis to tafamidis.
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
BridgeBio Pharma will present 28 abstracts on acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at the XX International Symposium on Amyloidosis (ISA) 2026. The data will highlight acoramidis's differentiated clinical profile, including its safety and efficacy in patients with chronic kidney disease, effects on cardiorenal function, and real-world outcomes compared to other treatments. These presentations aim to reinforce acoramidis as a leading first-line treatment option for ATTR-CM.
What BridgeBio Pharma Holders Bought Into
BridgeBio Pharma shareholders saw a 24.1% return over the past year, reflecting differing analyst views on its potential. Bullish forecasts focused on Attruby's momentum and late-stage programs, while cautious views highlighted reliance on a single franchise and high operating costs. The company's Q3 2026 revenue of US$353.2 million supported growth, but the profitability thesis remains unproven as it still reported a significant loss.
BridgeBio to Participate in November and December Investor Conferences
BridgeBio Pharma Inc. announced that its management team will participate in four investor conferences in November and December 2026. The company will hold fireside chats at these healthcare investor conferences, with live webcasts and replays available on its investor relations website for 30 days. This announcement is a routine investor-relations step and does not contain new business or financial information.
How Investors Are Reacting To BridgeBio Pharma (BBIO) Stronger Quarterly Results
BridgeBio Pharma reported stronger Q3 2026 results with US$353.17 million in revenue and a net loss of US$56.71 million, showing improvement year-over-year. The company's investment narrative continues to center on Attruby and late-stage rare disease programs, with recent equity grants aiming to support future commercial operations and program launches. Analysts project significant revenue and earnings growth by 2029, suggesting a potential 45% upside to its current price.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced equity grants to 80 new employees, totaling 147,578 restricted stock units. These grants, approved on November 5, 2026, are intended as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The awards will vest over time, subject to continued employment.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced equity grants to 80 new employees, consisting of restricted stock units for an aggregate of 147,578 shares of the company's common stock. These awards were approved by the compensation committee on November 5, 2026, as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants will vest over time, with the first portion vesting on November 16, 2027, subject to continued employment.
BridgeBio Pharma (BBIO) Cut Losses And Grew Revenue, Is The Stock Still Undervalued?
BridgeBio Pharma (BBIO) recently reported third-quarter 2026 results with US$353.17 million in revenue and a reduced net loss of US$56.71 million. The stock currently trades around US$74.27, with mixed short-term performance but strong long-term returns. While Simply Wall St's "Most Popular Narrative" pegs the fair value at a significantly lower $25.00 due to commercial risks and competition from Pfizer, another perspective based on discounted cash flows suggests the stock is deeply undervalued at $313.48 per share.
Achondroplasia Pipeline Report 2026: Discover Novel Drug Candidates, Ongoing Trials, and Major Players Shaping Future Care | BioMarin Pharma, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi
A new report by DelveInsight details the Achondroplasia pipeline for 2026, highlighting over 10 key companies developing novel treatments. The report outlines ongoing clinical trials, therapeutic mechanisms, and market growth prospects. Key companies include BioMarin Pharmaceuticals and BridgeBio/QED Therapeutics, with several therapies nearing significant regulatory milestones like FDA approvals.
BridgeBio Pharma stock nears key BBP-418 FDA decision
BridgeBio Pharma is nearing a crucial FDA decision for its BBP-418 drug, with a PDUFA date set for November 27, 2026. The company also reported strong third-quarter revenue of USD 353.2 million, driven by Attruby sales and a Bayer sales milestone. Additionally, BridgeBio has two other Priority Review decisions scheduled for oral infigratinib and encaleret in early 2027.
At $72.85 a share, BridgeBio Pharma (BBIO) executive sells 2,000 shares under a trading plan.
Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma (BBIO), sold 2,000 shares of common stock at $72.85 per share on October 30, 2026. This transaction was conducted under a Rule 10b5-1 sales plan established on September 8, 2025. Following the sale, Apuli directly holds 120,687 shares of the company.
BridgeBio Pharma, Inc. (2CL.F) Seasonal Returns Chart - Yahoo Finance
The article displays the seasonal returns chart for BridgeBio Pharma, Inc. (2CL.F), showing the average monthly price return from 2019 to 2026. As of November 3, the stock closed at 67.39 EUR, marking a 1.94% increase. The content indicates that the chart allows for analysis across different timeframes (3Y, 5Y, 10Y, 20Y, All).
Six heart research posters are set for the American Heart Association meeting.
BridgeBio Pharma (BBIO) will present new data on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM) at the American Heart Association Scientific Sessions in Chicago from November 6-9, 2026. The presentations will include analyses on heart failure events, cardiovascular hospitalizations, and mortality related to ATTR-CM, further strengthening acoramidis's profile as a first-line treatment. Six posters, including two moderated and one Abbott Laboratories-led, will be featured, focusing on detection, effects of acoramidis, and recovery insights.
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
BridgeBio Pharma, Inc. announced upcoming presentations at the American Heart Association (AHA) Scientific Sessions 2026, where new data on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared. The data aims to reinforce acoramidis's clinical profile as a first-line treatment for ATTR-CM, highlighting its near-complete TTR stabilization. Presentations will cover various aspects including diagnostic methods, effects on heart failure events, and risk of hospitalizations in ATTR-CM patients.
BridgeBio Pharma, Inc. (BBIO) stock price, news, quote and history
This article provides a detailed overview of BridgeBio Pharma, Inc. (BBIO), including its current stock price, recent performance, and key financial metrics. It highlights the company's focus on developing medicines for genetic diseases and lists several of its pipeline products in various clinical stages. The report also includes analyst ratings and a comparison of BBIO's returns against the S&P 500.
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
BridgeBio Pharma, Inc. will present new data on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM) at the American Heart Association Scientific Sessions 2026. The presentations will highlight acoramidis's differentiated clinical profile, reinforcing its position as a first-line treatment for ATTR-CM, and include moderated posters and poster presentations on the drug's effects on heart failure events and diagnostic approaches. The data further support acoramidis (Attruby® / BEYONTTRA®) as a near-complete TTR stabilizer approved for ATTR-CM treatment.
BridgeBio Pharma, Inc. (BBIO) stock price, news, quote and history - Yahoo Finance
This Yahoo Finance page provides a comprehensive overview of BridgeBio Pharma, Inc. (BBIO) stock, including its current price, news, historical data, and analyst insights. The stock closed at $74.03, down 1.29%, with after-hours trading showing no change. Recent news highlights include Q3 earnings reports, FDA priority reviews for new drugs, and analyses from Simply Wall St. and Zacks regarding the company's valuation and pipeline progress.
BridgeBio Pharma, Inc. (1BBIO.MI) Seasonal returns chart
This article provides a seasonal returns chart for BridgeBio Pharma, Inc. (1BBIO.MI), displaying the average monthly price return from 2025 to 2026. The information is presented on Yahoo Finance, showing the current stock price and daily percentage change.
BridgeBio Pharma, Inc. Stock 12‑Month Price Target Cut to $109.44, Implies 55% Upside
BridgeBio Pharma, Inc.'s average price target has been adjusted to $109.44 from $110.47, implying a 55% potential upside from its Oct. 29 closing price. This revised target is based on estimates from 18 analysts, with a consensus "Buy" rating maintained across 23 covering analysts.
BridgeBio Pharma Q3 2026 Earnings Call Transcript
BridgeBio Pharma reported strong financial results for Q3 2026, with total revenues of $353.2 million, driven by acoramidis sales and a $75 million milestone from Bayer. The company is preparing for three significant product launches—BBP-418, infigratinib, and encaleret—all under priority review with the FDA. BridgeBio remains confident in its acoramidis franchise, projecting $4 billion in peak-year sales, and highlights compelling real-world evidence differentiating it from competitors.
BridgeBio Pharma, Inc. (BBIO) Seasonal returns chart
This article presents a seasonality chart for BridgeBio Pharma, Inc. (BBIO), detailing the average monthly price return from 2019 to 2026. It also includes current stock information, showing BBIO trading at 73.66 USD with a 4.14% increase as of 12:04:33 pm GMT-4. The page also mentions the company's Q3 2026 earnings call replay.
BridgeBio Pharma Inc. (BBIO) Tops Q3 EPS by 14c
BridgeBio Pharma Inc. (BBIO) reported Q3 EPS of ($0.42), surpassing the analyst estimate of ($0.56) by $0.14. The company's revenue for the quarter was $353.17 million, exceeding the consensus estimate of $281.65 million. This financial performance indicates stronger-than-expected results for BridgeBio in the third quarter.
BlackRock Reveals 5.1% Ownership Stake in BridgeBio Pharma via Schedule 13G Filing
BlackRock, Inc. has disclosed a 5.1% beneficial ownership stake in BridgeBio Pharma, Inc., totaling 9,892,226 shares of common stock. This information was reported in a Schedule 13G filing with the SEC on October 27, 2026, with the triggering event date being September 30, 2026. BlackRock holds sole voting power over 9,576,011 shares and sole dispositive power over all 9,892,226 shares, confirming the acquisition was in the ordinary course of business.
BlackRock reports sole voting power over 9.58 million BridgeBio Pharma (BBIO) shares.
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in BridgeBio Pharma, Inc. (BBIO), totaling 9,892,226 common shares as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 9,576,011 shares and sole dispositive power over all 9,892,226 shares, with no shared voting or dispositive power. This Schedule 13G filing details BlackRock's passive investment in the biotechnology company.
Piper Sandler Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)
Piper Sandler analyst Biren Amin has maintained a Buy rating on BridgeBio Oncology Therapeutics (BBOT) with a price target of $21.00. This aligns with a general "Strong Buy" consensus among analysts for BBOT, despite the company reporting a quarterly GAAP net loss of $56.45 million for the quarter ending June 30, a significant increase from the previous year. Several other firms, including Morgan Stanley, Oppenheimer, JPMorgan, Leerink, and Raymond James, have recently lowered their price targets for BridgeBio Oncology.
BridgeBio Pharma, Inc. Estimates – NASDAQ:BBIO
This article provides an overview of BridgeBio Pharma, Inc. (NASDAQ:BBIO) financial estimates and actuals on TradingView. It covers income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare reported data with analyst estimates and visualize trends. The platform includes a disclaimer that the information is not investment advice.
How Investors May Respond To BridgeBio Pharma (BBIO) Positive Drug Data
BridgeBio Pharma recently released positive peer-reviewed and real-world data for acoramidis in ATTR-CM, alongside Phase 3 readouts and regulatory progress for encaleret in ADH1 and chronic hypoparathyroidism. These developments reinforce the company's strategy of building multiple rare disease revenue streams beyond a single product. Analysts are projecting aggressive growth, with revenue expected to increase by 62.1% annually and earnings to swing from a loss of US$691.9m today to a forecast of US$1.0b by 2029, assuming successful execution of their pipeline.
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced it will release its third quarter 2026 financial results and business updates after market close on Thursday, October 29, 2026. The company will host a conference call at 4:30 pm ET on the same day to discuss the results and program updates. Interested parties can access the live webcast via the Investors section of BridgeBio's website.
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced it will release its third quarter 2026 financial results and business updates after market close on Thursday, October 29, 2026. The company will host a conference call at 4:30 pm ET on the same day to discuss these results and program updates. A live webcast and replay will be available on the Investors section of BridgeBio's website.
Citigroup cuts target for BridgeBio Pharma stock to USD 91.00
Citigroup has reduced its price target for BridgeBio Pharma (BBIO) stock from USD 94.00 to USD 91.00, maintaining a neutral rating. This new target is 34.70 percent above the Nasdaq price of USD 67.56 on October 20, 2026, but remains below the broader analyst average of USD 104.90. The company reported a 120.40 percent increase in second-quarter revenue to USD 243.68 million, despite a net loss, and is scheduled to release its third-quarter results on October 28, 2026.
BridgeBio Pharma (BBIO) Draws Fresh Attention, Is The Pullback A Valuation Opportunity?
BridgeBio Pharma (BBIO) has gained renewed attention after new data for its ATTR-CM drug acoramidis showed replicated benefits, leading to a recent share price rebound after months of decline. The company now trades at a steep discount to analyst targets and some intrinsic value estimates, sparking debate on whether this is a valuation opportunity or a reflection of significant commercial execution risks. Conflicting valuation narratives exist, with Simply Wall St's leading narrative suggesting a 172% overvaluation, while a DCF model points to a heavy discount.
BridgeBio Pharma (BBIO) Advances Late Stage Programs, Is The Valuation Still Pricey?
BridgeBio Pharma (BBIO) has recently announced several late-stage program updates, including new data for Attruby and encaleret, and regulatory progress for oral infigratinib. Despite these advancements, the company's valuation remains a point of contention among analysts. While some market narratives suggest the stock is significantly overvalued, Simply Wall St's DCF model indicates it might be deeply discounted, leading to mixed messages on its true fair value.
Lobbying Update: $510,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed
BridgeBio Pharma Inc. disclosed $510,000 in lobbying expenditures for Q3 2026, covering issues like orphan drug policies and PBM reform. The article also details recent congressional and insider trading activity in BBIO stock, hedge fund movements, and analyst price targets for the company.
BofA Securities Lowers Price Target on BridgeBio Pharma to $102 From $104, Maintains Buy Rating
BofA Securities has reduced its price target for BridgeBio Pharma (BBIO) to $102 from $104, while still maintaining a Buy rating on the stock. Despite the lowered target, the average analyst rating for BridgeBio Pharma remains a "buy" with a mean price target of $111.16. The full MT Newswires article is behind a premium paywall.
BBIO Maintains Rating by Citigroup -- Price Target Lowered to $9
Citigroup maintained a neutral rating on BridgeBio Pharma (BBIO), lowering its price target from $94.00 to $91.00. While GuruFocus indicates BBIO is undervalued with a GF Value™ of $167.27 compared to its current price of $67.94, the company faces challenges with low financial strength and valuation scores, alongside significant insider selling. Investors are advised to exercise caution due to mixed signals and potential risks despite growth potential.
BBIO Maintained by Piper Sandler -- Price Target Raised to $120
Piper Sandler has maintained an Overweight rating on BridgeBio Pharma (BBIO) and increased its price target to $120.00, reflecting confidence in the company's growth potential in the biotechnology sector. Despite being considered 59.4% undervalued by GuruFocus's GF Value, the company faces challenges with financial strength and profitability, evidenced by significant insider selling. Investors are advised to weigh growth prospects against financial risks and insider activity.